Loading...

PTGX PROTAGONIST THERAPEUTICS INC Product Launches 8-K Filing

PRTG

PTGX

PROTAGONIST THERAPEUTICS INC

(PTGX)

2025 8-K

Financial Results Update

Financial Statements

Financial Statements

Regulatory Agreement

Study Results Update

Clinical Study Results

Positive Study Results

Financial Results

Management Change

Contract Amendment

Q3 Financial Results

Financial Results

Annual Meeting and Amendmen...

Financial Results

Financial Results

Collaboration Agreement wit...

Presentation at Conference

Regulation FD Disclosure

Financial Results

Appointment of Director

Financial Results

Product Updates

Annual Meeting Results

Financial Results

Underwriting Agreement

Financial Results

Management Changes

Management Change

External Links:

Protagonist Therapeutics amended its March 10, 2025 filing to correct the p value for clinical remission results from its Phase 2b ANTHEM-UC study of icotrokinra, changing it from p<0.001 to p<0.01, while also announcing positive results for the drug in ulcerative colitis and plaque psoriasis on March 8 and 10, 2025.

AI Assistant

PROTAGONIST THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.